Contents

Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion (COPERNICUS)

July 1, 2014

Clinical trial

Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.

Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, Ma Y, Stemper B, Zeitz O, Sandbrink R, Haller JA.

Ophthalmology. 2014 Jul;121(7):1414-1420.e1.
Full text | Metrics.

Main finding: Aflibercept significantly improved vision and decreased macular oedema, with greatest improvement in the first 24 weeks during fixed intravitreal Aflibercept dosing.

 

  • Purpose: To evaluate the efficacy and safety of intravitreal aflibercept injection for the treatment of macular edema secondary to central retinal vein occlusion.
  • Study type: Randomized controlled trial.
  • Condition: Central retinal vein occlusion

Participants: ≥18 yo with centre-involving macular oedema secondary to BRVO, BCVA 20/40-20/320, mean central subfield thickness ≥250 μm

 

  • n=188

 

Intervention:

 

 

Outcomes Time point AFLI + AFLI PRN/Sham Sham + AFLI PRN
Gained ≥15 letters Week 24 56.1% 12.3%
Week 52 55.3% 30.1%
Week 100 49.1% 23.3%
BCVA change from baseline Week 24 +17.3 -4.0
Week 52 +16.2 +3.8
Week 100 +13.0 +1.5

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2025 - sourceshed